Summary
Global Markets Direct’s, ‘Neisseria meningitidis Infections - Pipeline Review, H1 2016’, provides an overview of the Neisseria meningitidis Infections pipeline landscape.
The report provides comprehensive information on the therapeutics under development for Neisseria meningitidis Infections, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Neisseria meningitidis Infections and features dormant and discontinued projects.
Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.
Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.
Scope
- The report provides a snapshot of the global therapeutic landscape of Neisseria meningitidis Infections
- The report reviews pipeline therapeutics for Neisseria meningitidis Infections by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved Neisseria meningitidis Infections therapeutics and enlists all their major and minor projects
- The report assesses Neisseria meningitidis Infections therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news related to pipeline therapeutics for Neisseria meningitidis Infections
Reasons to buy
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of therapeutics under development for Neisseria meningitidis Infections
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Neisseria meningitidis Infections pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Companies Mentioned
Beijing Minhai Biotechnology Co., Ltd
Beijing Tiantan Biological Products Co., Ltd.
Biological E. Limited
GlaxoSmithKline Plc
ImmunoBiology Limited
JN-International Medical Corporation
MGB Biopharma Limited
Panacea Biotec Limited
Pfizer Inc.
Sanofi Pasteur SA
Serum Institute of India Limited
Wellstat Vaccines, LLC
'
Table of Contents
Table of Contents 2
List of Tables 7
List of Figures 8
Introduction 9
Global Markets Direct Report Coverage 9
Neisseria meningitidis Infections Overview 10
Therapeutics Development 11
Pipeline Products for Neisseria meningitidis Infections – Overview 11
Pipeline Products for Neisseria meningitidis Infections – Comparative Analysis 12
Neisseria meningitidis Infections – Therapeutics under Development by Companies 13
Neisseria meningitidis Infections – Therapeutics under Investigation by Universities/Institutes 14
Neisseria meningitidis Infections – Pipeline Products Glance 15
Late Stage Products 15
Clinical Stage Products 16
Early Stage Products 17
Neisseria meningitidis Infections – Products under Development by Companies 18
Neisseria meningitidis Infections – Products under Investigation by Universities/Institutes 19
Neisseria meningitidis Infections – Companies Involved in Therapeutics Development 20
Beijing Minhai Biotechnology Co., Ltd 20
Beijing Tiantan Biological Products Co., Ltd. 21
Biological E. Limited 22
GlaxoSmithKline Plc 23
ImmunoBiology Limited 24
JN-International Medical Corporation 25
MGB Biopharma Limited 26
Panacea Biotec Limited 27
Pfizer Inc. 28
Sanofi Pasteur SA 29
Serum Institute of India Limited 30
Wellstat Vaccines, LLC 31
Neisseria meningitidis Infections – Therapeutics Assessment 32
Assessment by Monotherapy Products 32
Assessment by Combination Products 33
Assessment by Target 34
Assessment by Mechanism of Action 36
Assessment by Route of Administration 37
Assessment by Molecule Type 39
Drug Profiles 41
(diphtheria + Haemophilus influenzae [serotype B] + hepatitis B + meningococcal [serotype C] + pertussis (whole-cell) + poliomyelitis + tetanus) (7-valent) vaccine - Drug Profile 41
Product Description 41
Mechanism of Action 41
R&D Progress 41
(meningococcal [serotype X] + tetanus) (monovalent) vaccine - Drug Profile 42
Product Description 42
Mechanism of Action 42
R&D Progress 42
MenBioVax - Drug Profile 43
Product Description 43
Mechanism of Action 43
R&D Progress 43
meningococcal [serotype B] vaccine - Drug Profile 44
Product Description 44
Mechanism of Action 44
R&D Progress 44
meningococcal [serotype B] vaccine - Drug Profile 46
Product Description 46
Mechanism of Action 46
R&D Progress 46
meningococcal [serotype B] vaccine - Drug Profile 48
Product Description 48
Mechanism of Action 48
R&D Progress 48
meningococcal [serotype B] vaccine - Drug Profile 49
Product Description 49
Mechanism of Action 49
R&D Progress 49
meningococcal [serotype B] vaccine - Drug Profile 50
Product Description 50
Mechanism of Action 50
R&D Progress 50
meningococcal [serotype B] vaccine - Drug Profile 51
Product Description 51
Mechanism of Action 51
R&D Progress 51
meningococcal [serotypes A, B, C, W-135, Y] (pentavalent) vaccine - Drug Profile 52
Product Description 52
Mechanism of Action 52
R&D Progress 52
meningococcal [serotypes A, C, W, Y] vaccine - Drug Profile 53
Product Description 53
Mechanism of Action 53
R&D Progress 53
meningococcal [serotypes A, C, W-135, Y] (tetravalent) vaccine - Drug Profile 54
Product Description 54
Mechanism of Action 54
R&D Progress 54
meningococcal [serotypes A, C, W-135, Y] (tetravalent) vaccine - Drug Profile 55
Product Description 55
Mechanism of Action 55
R&D Progress 55
meningococcal [serotypes A, C, W-135, Y] (tetravalent) vaccine - Drug Profile 56
Product Description 56
Mechanism of Action 56
R&D Progress 56
meningococcal [serotypes A, C, W-135, Y] (tetravalent) vaccine - Drug Profile 57
Product Description 57
Mechanism of Action 57
R&D Progress 57
meningococcal [serotypes A, C, W-135, Y] (tetravalent) vaccine 2 - Drug Profile 58
Product Description 58
Mechanism of Action 58
R&D Progress 58
meningococcal [serotypes A, C, W-135, Y] vaccine - Drug Profile 59
Product Description 59
Mechanism of Action 59
R&D Progress 59
meningococcal [serotypes A, C, W-135, Y] vaccine - Drug Profile 60
Product Description 60
Mechanism of Action 60
R&D Progress 60
meningococcal [serotypes A, C, W-135, Y] vaccine - Drug Profile 61
Product Description 61
Mechanism of Action 61
R&D Progress 61
meningococcal [serotypes A, C, W135, X, Y] vaccine - Drug Profile 63
Product Description 63
Mechanism of Action 63
R&D Progress 63
meningococcal [serotypes A, C, W135] vaccine - Drug Profile 64
Product Description 64
Mechanism of Action 64
R&D Progress 64
meningococcal [serotypes A, C] vaccine - Drug Profile 65
Product Description 65
Mechanism of Action 65
R&D Progress 65
meningococcal [serotypes C, Y] vaccine - Drug Profile 66
Product Description 66
Mechanism of Action 66
R&D Progress 66
meningococcal [strain C2135] vaccine - Drug Profile 67
Product Description 67
Mechanism of Action 67
R&D Progress 67
meningococcal vaccine - Drug Profile 68
Product Description 68
Mechanism of Action 68
R&D Progress 68
meningococcal vaccine 2 - Drug Profile 69
Product Description 69
Mechanism of Action 69
R&D Progress 69
MGBBP-3 - Drug Profile 70
Product Description 70
Mechanism of Action 70
R&D Progress 70
Neisseria meningitidis [serotype B] vaccine - Drug Profile 72
Product Description 72
Mechanism of Action 72
R&D Progress 72
Neisseria meningitidis [serotype B] vaccine - Drug Profile 73
Product Description 73
Mechanism of Action 73
R&D Progress 73
Nimenrix - Drug Profile 74
Product Description 74
Mechanism of Action 74
R&D Progress 74
TP-10 - Drug Profile 77
Product Description 77
Mechanism of Action 77
R&D Progress 77
Neisseria meningitidis Infections – Recent Pipeline Updates 78
Neisseria meningitidis Infections - Dormant Projects 86
Neisseria meningitidis Infections – Discontinued Products 89
Neisseria meningitidis Infections – Product Development Milestones 90
Featured News & Press Releases 90
Oct 09, 2015: Pfizer’s Phase 2 Study Demonstrates Safety, Tolerability and Immunogenicity of TRUMENBA When Coadministered with Meningococcal A, C, Y and W-135 Polysaccharide Conjugate and Tetanus, Diphtheria and Pertussis Vaccines in Adolescents 90
Aug 21, 2015: Pfizer Announces Positive Topline Results Of Two Phase 3 Studies Of TRUMENBA (Meningococcal Group B Vaccine) 91
Jun 24, 2015: CDC Advisory Committee on Immunization Practices Votes to Recommend Serogroup B Meningococcal Disease Vaccination including TRUMENBA for Adolescents and Young Adults 16 through 23 Years of Age 92
Jun 24, 2015: U.S. CDC committee recommends physicians make individual decisions on the use of meningococcal group B vaccines 93
May 01, 2015: GSK launches first vaccine to prevent meningococcal disease caused by meningococcus B in Brazil 93
Mar 29, 2015: GSK statement on meningitis vaccination in the UK 94
Feb 26, 2015: CDC Advisory Committee on Immunization Practices Votes to Recommend Serogroup B Meningococcal Disease Vaccination for Persons at Increased Risk 94
Feb 24, 2015: Pfizer Announces Positive Top-line Results Of A Phase 2 Study Of TRUMENBA Co-Administered With Routine Meningococcal (A, C, Y, and W) And Tetanus, Diptheria And Pertussis Vaccines In Adolescents 95
Jan 23, 2015: FDA approves a second vaccine to prevent serogroup B meningococcal disease 96
Nov 18, 2014: TRUMENBA (Meningococcal Group B Vaccine) is Now Available 97
Appendix 98
Methodology 98
Coverage 98
Secondary Research 98
Primary Research 98
Expert Panel Validation 98
Contact Us 98
Disclaimer 99
List of Tables
Number of Products under Development for Neisseria meningitidis Infections, H1 2016 11
Number of Products under Development for Neisseria meningitidis Infections – Comparative Analysis, H1 2016 12
Number of Products under Development by Companies, H1 2016 13
Number of Products under Investigation by Universities/Institutes, H1 2016 14
Comparative Analysis by Late Stage Development, H1 2016 15
Comparative Analysis by Clinical Stage Development, H1 2016 16
Comparative Analysis by Early Stage Development, H1 2016 17
Products under Development by Companies, H1 2016 18
Products under Investigation by Universities/Institutes, H1 2016 19
Neisseria meningitidis Infections – Pipeline by Beijing Its Minhai Biotechnology Co., Ltd, H1 2016 20
Neisseria meningitidis Infections – Pipeline by Beijing Tiantan Biological Products Co., Ltd., H1 2016 21
Neisseria meningitidis Infections – Pipeline by Biological E. Limited, H1 2016 22
Neisseria meningitidis Infections – Pipeline by GlaxoSmithKline Plc, H1 2016 23
Neisseria meningitidis Infections – Pipeline by ImmunoBiology Limited, H1 2016 24
Neisseria meningitidis Infections – Pipeline by JN-International Medical Corporation, H1 2016 25
Neisseria meningitidis Infections – Pipeline by MGB Biopharma Limited, H1 2016 26
Neisseria meningitidis Infections – Pipeline by Panacea Biotec Limited, H1 2016 27
Neisseria meningitidis Infections – Pipeline by Pfizer Inc., H1 2016 28
Neisseria meningitidis Infections – Pipeline by Sanofi Pasteur SA, H1 2016 29
Neisseria meningitidis Infections – Pipeline by Serum Institute of India Limited, H1 2016 30
Neisseria meningitidis Infections – Pipeline by Wellstat Vaccines, LLC, H1 2016 31
Assessment by Monotherapy Products, H1 2016 32
Assessment by Combination Products, H1 2016 33
Number of Products by Stage and Target, H1 2016 35
Number of Products by Stage and Mechanism of Action, H1 2016 36
Number of Products by Stage and Route of Administration, H1 2016 38
Number of Products by Stage and Molecule Type, H1 2016 40
Neisseria meningitidis Infections Therapeutics – Recent Pipeline Updates, H1 2016 78
Neisseria meningitidis Infections – Dormant Projects, H1 2016 86
Neisseria meningitidis Infections – Dormant Projects (Contd..1), H1 2016 87
Neisseria meningitidis Infections – Dormant Projects (Contd..2), H1 2016 88
Neisseria meningitidis Infections – Discontinued Products, H1 2016 89
List of Figures
Number of Products under Development for Neisseria meningitidis Infections, H1 2016 11
Number of Products under Development for Neisseria meningitidis Infections – Comparative Analysis, H1 2016 12
Number of Products under Development by Companies, H1 2016 13
Number of Products under Investigation by Universities/Institutes, H1 2016 14
Comparative Analysis by Clinical Stage Development, H1 2016 16
Comparative Analysis by Early Stage Products, H1 2016 17
Assessment by Monotherapy Products, H1 2016 32
Assessment by Combination Products, H1 2016 33
Number of Products by Targets, H1 2016 34
Number of Products by Stage and Targets, H1 2016 34
Number of Products by Routes of Administration, H1 2016 37
Number of Products by Stage and Routes of Administration, H1 2016 37
Number of Products by Molecule Types, H1 2016 39
Number of Products by Stage and Molecule Types, H1 2016 39
